The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
AT2Receptor Stimulation Increases Aortic Cyclic GMP in SHRSP by a Kinin-Dependent Mechanism
Abstract
In the present study we tested the hypothesis whether an angiotensin AT 2 receptor-mediated stimulation of the bradykinin (BK)/nitric oxide (NO) system can account for the effects of AT 1 receptor antagonism on aortic cGMP described previously in SHRSP. Adult SHRSP were treated for 4 hours with angiotensin II (ANG II) (30 ng/kg per min IV) or vehicle (0.9% NaCl IV). Animals were pretreated with vehicle, losartan (100 mg/kg PO), PD 123319 (30 mg/kg IV), losartan plus PD 123319, icatibant (500 μg/kg IV), N G-nitro-l-arginine methyl ester (L-NAME; 1 mg/kg IV), or minoxidil (3 mg/kg IV). Mean arterial blood pressure (MAP) was continuously monitored over the 4-hour experimental period, and plasma ANG II and aortic cGMP were measured by RIA at the end of the study. ANG II infusion over 4 hours raised MAP by about 20 mm Hg. Losartan alone or losartan plus ANG II as well as minoxidil plus ANG II markedly reduced blood pressure when compared to vehicle-treated or ANG II-treated animals, respectively. Plasma levels of ANG II were increased 2-fold by ANG II infusion alone or by ANG II in combination with icatibant, L-NAME, or minoxidil. The increase in plasma ANG II levels was even more pronounced after losartan treatment. Aortic cGMP content was significantly increased by ANG II, losartan, losartan plus ANG II, and minoxidil plus ANG II by 60%, 45%, 68%, and 52%, respectively (P<.05). The effects of ANG II and of losartan plus ANG II on aortic cGMP content were both blocked by cotreatment with the AT 2 receptor antagonist PD 123319. Icatibant and L-NAME abolished the effects of ANG II on aortic cGMP. Our results demonstrate the following: (1) ANG II increases aortic cGMP by an AT 2 receptor-mediated action because the effect could be prevented by an AT 2 receptor antagonist; (2) the effect of ANG II was not secondary to blood pressure increase because it remained under reduction of MAP with minoxidil; (3) losartan increased aortic cGMP most likely by increasing plasma ANG II levels with a subsequent stimulation of AT 2 receptors; and (4) the effects of AT 2 receptor stimulation are mediated by BK and, subsequently, NO because they were abolished by B 2 receptor blockade as well as by NO synthase inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin II receptors and angiotensin II receptor antagonists.
Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A., & Smith, R. D. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00446-6 · Cited by 1,853
Stoll, M., Steckelings, U. M., Paul, M., Bottari, S. P., Metzger, R., & Unger, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117710 · Cited by 906
Self-citationVascular smooth muscle. I. Normal structure, pathology, biochemistry, and biophysics.
Somlyo, A. P., & Somlyo, A. V. (1968) · PubMed · Cited by 881
Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Linz, W., Wiemer, G., Gohlke, P., Unger, T., & Schölkens, B. A. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06820-6 · Cited by 650
Self-citationLiu, Y. H., Yang, X. P., Sharov, V. G., Nass, O., Sabbah, H. N., Peterson, E., & Carretero, O. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119360 · Cited by 603
Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric Oxide
Brosnihan, K. B., Li, P., & Ferrario, C. M. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.523 · Cited by 404
Siragy, H. M., & Carey, R. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118630 · Cited by 314
Angiotensin Receptors and Their Therapeutic Implications
Greindling, K. K., Lassegue, B., & Alexander, R. W. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.001433 · Cited by 262
Coronary Kinin Generation Mediates Nitric Oxide Release After Angiotensin Receptor Stimulation
Seyedi, N., Xu, X., Nasjletti, A., & Hintze, T. H. (1995) · Hypertension · doi:10.1161/01.hyp.26.1.164 · Cited by 254
Pörsti, I., Bara, A. T., Busse, R., & Hecker, M. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb14787.x · Cited by 239
Cited by
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
Self-citationPhysiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739
Touyz, R. M., & Schiffrin, E. L. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01471-6 · Cited by 934
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
Tsutsumi, Y., Matsubara, H., Masaki, H., Kurihara, H., Murasawa, S., Takai, S., Miyazaki, M., Nozawa, Y., Ozono, R., Nakagawa, K., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7886 · Cited by 561
The role of the renin-angiotensin system in the development of cardiovascular disease
Unger, T. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02321-9 · Cited by 515
Self-citationPathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases
Matsubara, H. (1998) · Circulation Research · doi:10.1161/01.res.83.12.1182 · Cited by 478
Recent Progress in Angiotensin II Type 2 Receptor Research in the Cardiovascular System
Horiuchi, M., Akishita, M., & Dzau, V. J. (1999) · Hypertension · doi:10.1161/01.hyp.33.2.613 · Cited by 473
Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function
KASCHINA, E., & UNGER, T. (2003) · Blood Pressure · doi:10.1080/08037050310001057 · Cited by 458
Self-citationRole of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure and Renal Function
Carey, R. M., Wang, Z.-Q., & Siragy, H. M. (2000) · Hypertension · doi:10.1161/01.hyp.35.1.155 · Cited by 431
Dandona, P., Dhindsa, S., Ghanim, H., & Chaudhuri, A. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002101 · Cited by 386
Hornig, B., Landmesser, U., Kohler, C., Ahlersmann, D., Spiekermann, S., Christoph, A., Tatge, H., & Drexler, H. (2001) · Circulation · doi:10.1161/01.cir.103.6.799 · Cited by 341
Siragy, H. M., Inagami, T., Ichiki, T., & Carey, R. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6506 · Cited by 328
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Ichihara, S., Senbonmatsu, T., Price, E., Ichiki, T., Gaffney, F. A., & Inagami, T. (2001) · Circulation · doi:10.1161/01.cir.104.3.346 · Cited by 299
Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide
Berry, C., Touyz, R., Dominiczak, A. F., Webb, R. C., & Johns, D. G. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.6.h2337 · Cited by 259
The AT2 receptor—A matter of love and hate
Steckelings, U. M., Kaschina, E., & Unger, T. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.010 · Cited by 257
Self-citationSampson, A. K., Hilliard, L. M., Moritz, K. M., Thomas, M. C., Tikellis, C., Widdop, R. E., & Denton, K. M. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00256.2011 · Cited by 75
Acute effects of ACE inhibition on coronary endothelial dysfunction
Nickenig, G., Stäblein, A., Wassmann, S., Wyen, C., Müller, C., & Böhm, M. (2000) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2000.067 · Cited by 13
Metadata
- Authors
- Gohlke, P., Pees, C., & Unger, T.
- Venue
- Hypertension
- Published
- 1998-01
- Volume
- 31
- Issue
- 1
- Pages
- 349-355
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2104950980
- Cited by
- 395
- References
- 25
- FWCI
- 27.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.